Targeting a host element as a strategy to block HIV replication: Is it nice to fool with Mother Nature?

Current Opinion in HIV and AIDS

Volumn 4, Issue 2, 2009, Pages 79-81

  Lederman, Michael M ^a   Este, Jose ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; MARAVIROC; VACCINE; VICRIVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RECEPTOR;

ALLELE; ANTIVIRAL ACTIVITY; CARDIOVASCULAR RISK; CD4+ T LYMPHOCYTE; CELL CULTURE; DISEASE SEVERITY; DRUG TARGETING; EDITORIAL; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOSITY; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RESISTANCE; MORBIDITY; MORTALITY; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VIRUS REPLICATION; WEST NILE FLAVIVIRUS; DRUG ANTAGONISM;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, HIV;

EID: 65549132892     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283207b07     Document Type: Editorial

References (36)

1. Brass AL, Dykxhoorn DM, Benita Y, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319:921-926. (Pubitemid 351263756)
2. Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134:577-586.
3. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
4. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998; 62:1507-1515.
5. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377. (Pubitemid 26272077)
6. Salkowitz JR, Purvis SF, Meyerson H, et al. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001; 98:200-211. (Pubitemid 32150608)
7. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40. (Pubitemid 43139642)
8. Lederman MM. Host-directed and immune-based therapies for human immunodeficiency virus infection. Ann Intern Med 1995; 122:218-222.
9. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a metaanalysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-265. (Pubitemid 351263445)
10. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269. (Pubitemid 351263446)
11. Murphy PM. Chemokines. In: Paul WE, editor. Fundamental Immunology, Fifth edition Philadelphia: Lippincott Williams and Wilkins; 2003. pp. 801- 840.
12. Glass WG, Lim JK, Cholera R, et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-1098. (Pubitemid 41464502)
13. Shirato K, Kimura T, Mizutani T, et al. Different chemokine expression in lethal and nonlethal murine West Nile virus infection. J Med Virol 2004; 74:507-513. (Pubitemid 39281652)
14. Lederman MM, Sieg SF. CCR5 and its ligands: a new axis of evil? Nat Immunol 2007; 8:1283-1285.
15. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-1336. (Pubitemid 350131170)
16. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440. (Pubitemid 40321934)
17. Silvestri G, Paiardini M, Pandrea I, et al. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007; 117:3148-3154. (Pubitemid 350096967)
18. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-1455.
19. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1 Infected, treatment-experienced patients: AIDSClinical Trials Group 5211. J Infect Dis 2007; 196:304-312. (Pubitemid 47047471)
20. Lederman MM, Margolis L. The lymph node in HIV pathogenesis. Semin Immunol 2008; 20:187-195.
21. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627. (Pubitemid 39095778)
22. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-427. (Pubitemid 43122323)
23. Veillard NR, Kwak B, Pelli G, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94:253-261. (Pubitemid 38197459)
24. Zernecke A, Liehn EA, Gao JL, et al. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 2006; 107:4240-4243. (Pubitemid 43801346)
25. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-1181. (Pubitemid 23300886)
26. Mosier D. How HIV changes its tropism - evolution and adaptation. Curr Opin HIV AIDS 2008 (000-000).
27. Grivel JC, Margolis LB. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nat Med 1999; 5:344-346.
28. Quinones-Mateu ME, Ball SC, Marozsan AJ, et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74:9222-9233. (Pubitemid 30759625)
29. Troyer RM, Collins KR, Abraha A, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005; 79:9006-9018. (Pubitemid 40934811)
30. Melby T, Despirito M, Demasi R, et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006; 194:238-246. (Pubitemid 44087196)
31. Delwart EL, Mullins JI, Gupta P, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol 1998; 72:617-623. (Pubitemid 28048879)
32. Pillai SK, Good B, Pond SK, et al. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005; 79:1734-1742. (Pubitemid 40459119)
33. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 2006; 4:312-317.
34. Waters L, Mandalia S, Randell P, et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617-1623. (Pubitemid 351706746)
35. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44: 591-595. (Pubitemid 46233265)
36. Moncunill G, Armand-Ugon M, Pauls E, et al. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008; 22:23-31. (Pubitemid 350294874)